FDA issues complete response letter for quizartinib in relapsed/refractory FLT3-ITD AML June 25, 2019
FDA lifts partial clinical hold on phase III CANOVA trial of venetoclax in multiple myeloma June 25, 2019
Talzenna approved in E.U. for germline BRCA-mutated locally advanced or metastatic breast cancer June 25, 2019
RSS